

PATIENT• DOSAGE• COMPLIANCE

The illustration features a large green shield with a white cross inside, positioned above a product box. To the left of the box is a knight figure in red armor, holding a sword and a shield. The product box is for "AUGMERO- 1GM Meropenem Injection IP". The box includes text such as "Each vial contains : Meropenem Trihydrate (Sterile) IP 1000 mg", "Storage : Store in cool & dry place, below 25°C. Protect from light & moisture.", "Direction for use : Dissolve the contents of vial 20 ml. of Sterile water for injection IP. The reconstituted solution should be used immediately after preparation.", "Keep out of reach of children.", "Do not use if solution contains Particles / suspended matter.", and "AUGMERO- 1GM ऑग्मेरो इनजेक्शन". The box also features a logo with a stylized "A" and "U" and the text "For IV Use Only" and "1gm". The background is white with several orange COVID-19 virus particles floating around.

AUGMERO- 1GM
Injection

Description

Augmero IV (Meropenem for injection) is a sterile, proton, synthetic, broad spectrum carbapenem antibiotic for administration

Indication

Meropenem for Injection I.V. is indicated as single agent therapy for the treatment of :

- Adult and pediatric patients (\geq months of age) with complicated appendicitis and peritonitis caused by susceptible isolates of viridans group streptocci, Escherichia coli, Klebsiella pneumoniae, pseudomonas aeruginosa, Bacteroides fragilis, B.thetaiotaomicron, and Peptostreptococcus species.
- Adult and pediatric patients (\geq months of age) with complicated, skin and skin structure infections caused by susceptible isolates of Staphylococcus aureus (beta- lactamase and non-beta-lactamase-producing, methicillin-susceptible isolates only)
- Pediatric patients (\geq 3 months of age) with bacterial meningitis caused by susceptible isolates of S. pneumoniae, Haemophilus influenzae (beta - lactamase-and non-beta- lactamase- producing isolates.)

Mechanism of action:

Augmero has bactericidal action by interfering with bacterial cell wall synthesis of both gram positive and gram negative bacteria.

Dosage:

Patient	Indication	Dosage	Duration
Adult	Intra Abdominal Infection	1g 8 hourly	7-14 days
	Nosocomial Pneumonia	1g 8 hourly	4-7 days
	Skin or Soft tissue infection	500 mg- 1 gm 8 hourly	7-10 days
	Cystic Fibrosis	2 g 8 hourly	7- 10 days
	Meningitis	2g 8 hourly	7-21 days
	MIC value>4 mg/ml	2g 8 hourly	7-21 days
Renal Adult	CrCl 26-50 ml/min	1g 12 hourly	-
	CrCl 10- 25 ml/min	500 mg 12 hourly	-
	CrCl <9 ml/min	500 mg 24 hourly	-
Pediatric	Intra Abdominal Infection	20 mg/kg 8 hourly	-
	Meaninitis	40 mg/kg 8 hourly	-
	Skin and skin Structure infection	10 mg/kg 8 hourly	-

Strength: Augmero is available in 1 gm and 2 gm strength with WFI

Note: ● Meropenem 2 gm Q8H prolonged therapy infused over 3 hours

- Studies have demonstrated that three hour infusion improved the cumulative probability of target attainment compared to 30 minutes intermittent administration.
- Demonstrated the successful and safe utilization of maximal daily doses of 9000 mg for meropenem and 6000 mg for doripenem in patients with Cystic Fibrosis, when administered by 3- and 4 - hour prolonged infusions, respectively.

Mkt. By:

② Augurs Healthcare

Corp office : Kaiser - Joseph - Str.245,

79098 Freiburg I. Br.(Germany)

Regd. Office: C-17, Vibhuti Khand- 226016

✉ Email - wecare@augurshealthcare.com

Chemist 1.....2.....

Name of Company Rep.....

Mobile no.....